tirzepatide cardiovascular outcomes trial linked to lower risk for death, adverse CV and kidney vs. GLP-1s Effects of tirzepatide on circulatory – tirzepatide cardiovascular outcomes trial results

Due to their delivery route, oral peptides, like Healthletics Arginine Salt formulation, are often highlighted for this type of support

In a Phase II readout released in August 2022, the pharma touted a 15.6% drop in body weight in patients taking CagriSema, versus 5.1% in comparators on semaglutide alone and 8.1% in patients treated with only cagrilintide

Se excess can further lead to joint pain, muscle weakness, tremor, muscle spasms, ataxia, headache, confusion and memory loss, and, in more severe cases of intoxication, fever, hypotension, abnormal electrocardiogram, cardiac arrest, respiratory arrest, liver toxicity, delirium, coma, and death (51, 65, 66)

If you are considering it and the cost is not a barrier, it is unlikely to harm you and may provide a small benefit